Hieronder betreft de geschreven tekst van een podcast van juni 2010.
Tekst
IFCC Working Group for Standardization of Thyroid Function Tests
Een paar stukjes:
But first of all, with the implementation of the work in mind, we sought a broad representation of stakeholders in our group.
This was achieved by appointing members from the academic world, metrological institutes, producers of reference materials, the in vitro diagnostic industry, and last but not least, from the International Thyroid Associations.
Second, work was undertaken to lay the metrological foundation to standardization, which is based on a complete reference measurement system, which is preferably an SItraceable system, and comprising the measurant, reference materials, reference measurement procedures, and routine procedures.
And in the conviction that the reference measurement system needs international recognition, close cooperation with the Joint Committee for Traceability in Laboratory Medicine is required.
The abbreviation for that committee is JCTLM.
The JCTLM is indeed a worldwide platform to promote and give guidance on internationally recognized and accepted equivalence and traceability of measurements in laboratory medicine.
Making the link to the JCTLM was rather easy for our Working Group because I head the co-chair in one of the JCTLM Working Groups.
So what metrological tools were available at the start?
Well, only for total thyroid hormones was a complete SI-traceable
reference measurement system available.
In addition, the reference materials and isotope dilution, liquid
chromatography–tandem mass spectrometry reference measurement procedures were already listed in the database of the JCTLM.
For free thyroid hormones, the working group proposed to define operation and the measurant as T4 or T3 and a dialysate from equilibrium dialysis of serum or plasma prepared under defined conditions.
For the technical realization of the measurant at a hierarchically higher order, our Working Group chose the concept of an international conventional reference measurement procedure.
The convention was about the condition for equilibrium dialysis, but the quantification of the hormone in the dialysate was to be done with an isotope dilution mass spectrometry reference measurement
procedure.
Finally, for TSH measurement, the only metrological tool that was available was immunoanalysis, and because of the heterogeneity of this glycoprotein hormone, this is really mixture analysis, expressed in international units, defined by reference preparation from the World Health Organization.
When one looks into the three papers, one will see a great span in overall quality.
To give an example,
the total imprecision of the total T4 assays ranges from roughly 3-9%;
for free T4, from 1.5-14%;
for TSH, from 2.5-8%.
Well therefore, I think it is a great mistake to argue about the quality of, for example, free T4 immunoassays in general, because as you have seen from these figures, there are good ones as well as assays that need improvement
Okay. Well, coming to the standardization issue, could you comment on the standardization status of the different thyroid assays and the impact standardization would have?
And could you briefly also describe the process of standardization?
Dr. Linda Thienpont:
For total T4, our studies showed that the mean of the results from all immunoassays compared well with the IDMS reference method values.
In other words, the two high values seemed to balance the two lower ones.
In consequence, it is now the responsibility of the individual manufacturers to eliminate the assay-specific biases.
To solve this problem, manufacturers should follow the normal rule towards establishing traceability, which is cooperation with the JCTLM listed reference laboratory.
For total T3, the situation was quite different.
Standardization would cause a shift of the whole market to lower values.
Current values would decrease in average by roughly 15%.
(00:14:56)
For free hormones, the situation was even more pronounced, quite a the difference among the assays was seen and all were negatively biased in comparison to equilibrium dialysis mass spectrometry.
In consequence, standardization of free thyroid hormones will require a huge effort and will have a major clinical impact.
For free T3, the values would increase in average by roughly 15% but as for free T4, even by 35%.
The TSH was special in a sense.
It was amazing to see the agreement of so many assays, but very unfortunate to see that three assays caused up to 40% difference in results on average, even more pronounced in the low range.
One may question, whether this observation is clinically relevant?
Personally, I think it is.
The problem with TSH is that so called universal cut-off are used for defining subclinical hypothyroidism, mainly around about five milli international units per liter.
However, as the market is not standardized, assay specific rather than universal values should be used.
Also the discussion about lowering this value to 3 or even 2.5 milli international units per liter does not address this standardization problem.
In my opinion, it is one of the tragedies that these discussions neglect the standardization problems
(00:20:00)
Also, a much greater variety of challenging samples shall be included to explore the full impact of standardization, for example, specimens obtained from different patient categories or individuals with different pathologies, thyroid pathologies, and others and/or patients and the therapy.
This is of particular importance for standardization of free thyroid hormones and TSH measurements.
For the latter, there is indeed evidence of different glycoforms associated with hypothyroidism.
Thus, we really have to investigate whether certain assays perform differently with clinical samples.
Another point of concern for our working group is that it cannot be overlooked that standardization,
for example, of free thyroid hormone immunoassays
will cause a shift of the whole market to higher values, for some even by a factor of two.